# Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

> **NCT04494373** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 154 (estimated)

## Conditions studied

- Bone Metastasis From Solid Tumors

## Interventions

- **DRUG:** HS-20090
- **DRUG:** Xgeva®

## Key facts

- **NCT ID:** NCT04494373
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494373, "Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04494373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*